文献速递预防保健、筛查与疫苗慢病管理

ChAdOx1与BNT162b2新冠疫苗在英格兰卫生和社会照护工作者中的比较有效性:基于OpenSAFELY的队列研究

Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY.
PubMed 文献 · BMJ · 2022-07-20

结果显示两种疫苗各结局累积发生率相似,感染率差为2.04/1000人(95%CI 0.04至4.04),急诊和住院率差无统计学意义;接种后3-4周发病率急剧下降,提示两种疫苗对该相对年轻健康人群的Alpha变异株感染均有强保护。

要点

  • 两种疫苗首剂后20周内SARS-CoV-2感染累积发生率相似,差值为2.04/1000人。
  • 新冠相关急诊就诊和住院的累积发生率差值无统计学意义。
  • 接种后3-4周发病率急剧下降,此后新冠相关住院事件很少。

核心结论

  • 在卫生和社会照护工作者中,接种BNT162b2或ChAdOx1后20周内SARS-CoV-2感染和新冠疾病发生率无实质性差异。
  • 两种疫苗对该相对年轻健康人群的Alpha变异株新冠疾病均显示强保护。

研究设计与样本

  • 队列研究,模拟比较有效性试验,代表NHS England开展。
  • 数据来自OpenSAFELY-TPP研究平台链接的初级保健、医院和新冠监测记录,覆盖SARS-CoV-2 Alpha变异株优势流行期。

主要发现

  • 首剂接种后20周,BNT162b2组记录SARS-CoV-2感染的累积发生率为21.7/1000人(95%CI 20.9至22.4),ChAdOx1组为23.7/1000人(95%CI 21.8至25.6)。
  • 20周时新冠相关急诊就诊的累积发生率差为0.06/1000人(95%CI -0.31至0.43),新冠相关住院的累积发生率差为0.11/1000人(95%CI -0.22至0.44)。
  • 接种后3-4周发病率急剧下降,此后新冠相关急诊和住院事件很少。

临床怎么用

  • 在相对年轻健康的卫生和社会照护工作者中,BNT162b2与ChAdOx1两种疫苗均可提供对Alpha变异株新冠疾病的强保护。
  • 接种后3-4周起保护作用明显,临床可据此预期疫苗免疫建立时间。

局限性

  • 研究覆盖SARS-CoV-2 Alpha变异株优势流行期,结论外推至其他变异株需谨慎。
  • 研究对象为相对年轻健康的卫生和社会照护工作者,非临床极度脆弱人群,外推至其他人群受限。
  • 观察性队列设计,尽管模拟比较有效性试验,仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) covid-19 vaccines against infection and covid-19 disease in health and social care workers. DESIGN: Cohort study, emulating a comparative effectiveness trial, on behalf of NHS England. SETTING: Linked primary care, hospital, and covid-19 surveillance records available within the OpenSAFELY-TPP research platform, covering a period when the SARS-CoV-2 Alpha variant was dominant. PARTICIPANTS: 317 341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a general practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable. INTERVENTIONS: Vaccination with either BNT162b2 or ChAdOx1 administered as part of the national covid-19 vaccine roll-out. MAIN OUTCOME MEASURES: Recorded SARS-CoV-2 positive test, or covid-19 related attendance at an accident and emergency (A&E) department or hospital admission occurring within 20 weeks of receipt of the first vaccine dose. RESULTS: Over the duration of 118 771 person-years of follow-up there were 6962 positive SARS-CoV-2 tests, 282 covid-19 related A&E attendances, and 166 covid-19 related hospital admissions. The cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks after vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 20 weeks after first-dose vaccination with BNT162b2 was 21.7 per 1000 people (95% confidence interval 20.9 to 22.4) and with ChAdOx1 was 23.7 (21.8 to 25.6), representing a difference of 2.04 per 1000 people (0.04 to 4.04). The difference in the cumulative incidence per 1000 people of covid-19 related A&E attendance at 20 weeks was 0.06 per 1000 people (95% CI -0.31 to 0.43). For covid-19 related hospital admission, this difference was 0.11 per 1000 people (-0.22 to 0.44). CONCLUSIONS: In this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or covid-19 disease up to 20 weeks after vaccination. Incidence dropped sharply at 3-4 weeks after vaccination, and there were few covid-19 related hospital attendance and admission events after this period. This is in line with expected onset of vaccine induced immunity and suggests strong protection against Alpha variant covid-19 disease for both vaccines in this relatively young and healthy population of healthcare workers.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hulme WJ, Williamson EJ, Green ACA, et al. Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY. BMJ. 2022. PMID: 35858680. doi:10.1136/bmj-2021-068946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。